Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 3 × Lymphoma, B-Cell × Calcium Dobesilate × Clear all

Phase

Phase 1 2 Phase 3 1 Phase 2 1

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Multiple Myeloma 23 Precursor Cell Lymphoblastic Leukemia-Lymphoma 13 Burkitt Lymphoma 7 Leukemia 6 Lymphoma 4 Recurrence 3 Prostatic Neoplasms 3 Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 3 Parkinson Disease 4, Autosomal Dominant Lewy Body 2 Neoplasms, Plasma Cell 2 Leukemia, Biphenotypic, Acute 2 Immunoglobulin Light-chain Amyloidosis 2 Hodgkin Disease 2 Breast Neoplasms 2 Vomiting 1 Urinary Bladder Neoplasms 1 Ureteral Neoplasms 1 Smoldering Multiple Myeloma 1 Precursor B-Cell Lymphoblastic Leukemia-Lymphoma 1 Nausea 1 Malignant Neoplasms of Male Genital Organs 1 Lymphoma, Non-Hodgkin 1 Lymphoma, Follicular 1 Lymphoma, B-Cell 1 Leukemia, Myelomonocytic, Chronic 1 Inflammatory Breast Neoplasms 1 Hypersensitivity 1 Hematologic Neoplasms 1 Hematologic Diseases 1 Down Syndrome 1

Interventions

Rituximab 12 pirtobrutinib 5 ibrutinib 4 Vincristine 3 Doxorubicin 3 Cytarabine 3 zanubrutinib 2 Prednisone 2 Etoposide 2 Cyclophosphamide 2 Bendamustine Hydrochloride 2 venetoclax 1 tositumomab I-131 1 idelalisib 1 ibritumomab tiuxetan 1 etoposide phosphate 1 entecavir 1 cirmtuzumab 1 axicabtagene ciloleucel 1 acalabrutinib 1 VAP-cyclo protocol 1 Tenofovir 1 Radiotherapy 1 Methotrexate 1 Melphalan 1 Ifosfamide 1 Gemcitabine 1 Drug Therapy 1 Dexamethasone 1 Cisplatin 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT06230224 2026-02-06

OLYMPIA-4

Regeneron Pharmaceuticals

Phase 3 Recruiting

Lymphoma, Non-Hodgkin, Lymphoma, B-Cell

Data powered by HemOnc (CC BY 4.0) Colophon ⚡